Vismodegib induces significant clinical response in locally advanced trichoblastic carcinoma.
Fiche publication
Date publication
mai 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CRIBIER Bernard
Tous les auteurs :
Lepesant P, Crinquette M, Alkeraye S, Mirabel X, Dziwniel V, Cribier B, Mortier L
Lien Pubmed
Résumé
Patients with advanced basal cell carcinoma (BCC), due to local extension or metastatic disease, were previously in a therapeutic impasse. Targeted inhibition of the sonic hedgehog pathway by vismodegib represents a new therapeutic strategy. Adnexal carcinomas are rare malignant skin tumors derived from epithelial annexes. This article is protected by copyright. All rights reserved.
Référence
Br J Dermatol. 2015 May 22